This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Sep 19;374(9694):952-954.

doi: 10.1016/S0140-6736(09)61562-2. Epub 2009 Aug 31.

Risk of combining PPIs with thienopyridines: fact or fiction?

Dirk Sibbing¹, Adnan Kastrati²

Affiliations

Affiliations

¹ Deutsches Herzzentrum München und 1 Medizinische Klinik rechts der Isar, Technische Universität München, 80636 Munich, Germany. Electronic address: dirk@sibbing.net.
² Deutsches Herzzentrum München und 1 Medizinische Klinik rechts der Isar, Technische Universität München, 80636 Munich, Germany.

PMID: 19726077
DOI: 10.1016/S0140-6736(09)61562-2

Comment

Risk of combining PPIs with thienopyridines: fact or fiction?

Dirk Sibbing et al. Lancet. 2009.

. 2009 Sep 19;374(9694):952-954.

doi: 10.1016/S0140-6736(09)61562-2. Epub 2009 Aug 31.

Authors

Dirk Sibbing¹, Adnan Kastrati²

Affiliations

¹ Deutsches Herzzentrum München und 1 Medizinische Klinik rechts der Isar, Technische Universität München, 80636 Munich, Germany. Electronic address: dirk@sibbing.net.
² Deutsches Herzzentrum München und 1 Medizinische Klinik rechts der Isar, Technische Universität München, 80636 Munich, Germany.

PMID: 19726077
DOI: 10.1016/S0140-6736(09)61562-2

No abstract available

PubMed Disclaimer

Comment on

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. O'Donoghue ML, et al. Lancet. 2009 Sep 19;374(9694):989-997. doi: 10.1016/S0140-6736(09)61525-7. Epub 2009 Aug 31. Lancet. 2009. PMID: 19726078 Review.

Similar articles

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. Abraham NS, et al. Am J Gastroenterol. 2010 Dec;105(12):2533-49. doi: 10.1038/ajg.2010.445. Am J Gastroenterol. 2010. PMID: 21131924 Review. No abstract available.
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA. Abraham NS, et al. Circulation. 2010 Dec 14;122(24):2619-33. doi: 10.1161/CIR.0b013e318202f701. Epub 2010 Nov 8. Circulation. 2010. PMID: 21060077 Review. No abstract available.
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. O'Donoghue ML, et al. Lancet. 2009 Sep 19;374(9694):989-997. doi: 10.1016/S0140-6736(09)61525-7. Epub 2009 Aug 31. Lancet. 2009. PMID: 19726078 Review.
A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T. Hagihara K, et al. Drug Metab Dispos. 2009 Nov;37(11):2145-52. doi: 10.1124/dmd.109.028498. Epub 2009 Aug 24. Drug Metab Dispos. 2009. PMID: 19704027
Proton pump inhibitor and clopidogrel interaction: fact or fiction?
Laine L, Hennekens C. Laine L, et al. Am J Gastroenterol. 2010 Jan;105(1):34-41. doi: 10.1038/ajg.2009.638. Epub 2009 Nov 10. Am J Gastroenterol. 2010. PMID: 19904241 Review.

See all similar articles

Cited by

Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents.
Johnson DA. Johnson DA. Curr Gastroenterol Rep. 2010 Jun;12(3):167-74. doi: 10.1007/s11894-010-0103-6. Curr Gastroenterol Rep. 2010. PMID: 20425476 Review.
How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?
Sherwood MW, Wang TY, Becker RC. Sherwood MW, et al. Curr Treat Options Cardiovasc Med. 2011 Feb;13(1):46-56. doi: 10.1007/s11936-010-0107-4. Curr Treat Options Cardiovasc Med. 2011. PMID: 21136215
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?
Singh M, Shah T, Adigopula S, Molnar J, Ahmed A, Khosla S, Arora R. Singh M, et al. Indian Heart J. 2012 Jul-Aug;64(4):341-52. doi: 10.1016/j.ihj.2012.06.003. Epub 2012 Jun 21. Indian Heart J. 2012. PMID: 22929815 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information